In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological signi®cance of chromosome 9 deletions in super®cial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P=0.022). Female patients had more chromosome 9q LOH than male patients did (P=0.010). Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred signi®cantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions con®rmed the correlation (P=0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of super®cial bladder cancer. Oncogene (2000) 19, 6317 ± 6323.
Introduction
Bladder cancer is characterized by frequent genetic alterations of chromosome 9. These include monosomy 9 but also more localized deletions of various chromosomal regions. Re®ned deletion mapping with microsatellite markers has suggested the existence of several putative tumor suppressor loci on this chromosome at 9p22-23, 9p21-22, 9p11-13, 9q12-13, 9q21-22, 9q31 and 9q33-34 (Habuchi et al., 1995; Simoneau et al., 1996; Czerniak et al., 1999; Simoneau et al., 1999) . Chromosome 9 deletions have been found in tumors of various grades and stages, however, in low stage tumors, they are often the only genetic anomaly identi®ed. In a previous study of chromosome 9 LOH on a series of 139 primary Ta, T1 bladder tumors obtained at initial diagnosis (Simoneau et al., 1999) we found deletion of at least one chromosome 9 marker in 48% of tumors. Chromosome 9 monosomy was a rare event and deletions on 9q were twice as frequent as deletions on 9p. Moreover, only 4% of cases had deletions on 9p only. This suggests that inactivation of one or more tumor suppressor genes on the long arm of chromosome 9 may be an early event in the tumorigenic pathway leading to papillary tumors. The lower incidence of chromosome 9 anomalies in higher stage tumors reported in other studies is consistent with this hypothesis (Tsai et al., 1990; Dalbagni et al., 1993; Spruck et al., 1994) .
Recently, Czerniak et al., (1999) , in elegant genetic mapping studies of cystectomy specimens, found deletions of chromosome 9 in normal appearing urothelium adjacent to areas of the urinary bladder mucosa exhibiting early precursor changes. They observed a clonal relationship among multiple samples from the same patients and suggested several regions on 9q that may contain critical genes for the development of urothelial neoplasia. This hypothesis was further enforced by the detection of chromosome 9 deletions in cells from voided urine samples of patients followed up after resection of transitional cell carcinoma (TCC), at a time when no tumor was detectable and urine cytologies were negative.
One of the most important features of papillary bladder tumors is the high rate of recurrence after initial treatment. Pre-malignant ®eld changes unidenti®ed at the time of initial resection are likely to be the cause of these tumor re-growths. We previously showed that expression of antigen markers de®ned by monoclonal antibodies were associated with independent risk of tumor recurrence (Allard et al., 1995) . Mapping studies of normal appearing urothelium in patients with tumors have shown frequent expression of these antigens in otherwise normal cells (Lee et al., 1997; Rao et al., 1993) . Bartlett et al., (1998) recently suggested that loss of chromosome 9 as detected by Fish analysis of the pericentromeric satellite marker at 9q12 characterized tumors at high risk of recurrence. Moreover they observed a great homogeneity of chromosome 9 copy number between multiple synchronous tumors and between the primary and recurrent tumors.
Thus there is growing evidence that recurrent super®cial papillary tumors originate from ®eld changes that may be monoclonal in origin. We hypothesized that identifying genes on chromosome 9 associated with early tumor recurrence may indicate their implication in early carcinogenesis. We thus correlated the frequency of LOH at 28 microsatellite markers with clinical outcome in 133 initial low stage tumors that were part of an epidemiological study providing veri®ed clinical information at initial diagnosis (Allard et al., 1995) . After up to 8 years of follow-up, (5.6 years median) 69% of these patients suered at least one recurrence but only 3% progressed to muscle-invasive disease. This low progression rate marks these tumors as typical of the super®cial papillary bladder tumor pathway. In the present study, we used these data to evaluate the potential biological signi®cance of chromosome 9 anomalies in super®cial tumors at initial diagnosis, particularly with regard to recurrence.
Results
Our initial study, which suggested ®ve candidate tumor suppressor loci on chromosome 9, included 139 patients with initial low stage tumors in whom DNA was available from the initial tumor and from peripheral blood lymphocytes (Simoneau et al., 1999) . The present study includes 133 of these patients for whom we have complete follow-up data for up to 8 years with a median follow-up time of 5.6 years ( Table  1 ). The mean age of these 133 patients was 61.7 years and the male : female ratio was 3 : 1. Most of their bladder tumors were stage Ta (105/133), single (97/133) and 3 cm or less in diameter (73/126). Grade 1 papillary tumors were found in 44 (33%) of the patients, while grade 2 tumors were found in 77 (58%) and grade 3 in 12 (9%). Only 21 patients had never smoked a cigarette. Recurrence occurred in 96 patients but only four of these suered progression to muscle-invasive disease.
Chromosome 9 deletions in relation to patient and tumor characteristics
The frequency of allelic deletions (LOH) for each marker analysed along chromosome 9 is illustrated in Figure 1 according to pathological characteristics of the tumors. There was a great deal of variability in LOH frequency for the dierent microsatellite markers analysed but overall, deletions on 9q were twice as common as deletions on 9p in our tumor population (Simoneau et al., 1999) . There was no signi®cant dierence in LOH frequency according to stage or number of tumors (Figure 1a,c) . However, for all markers analysed, an association was found between the frequency of deletion and grade with grade 2 ± 3 tumors having a higher frequency of deletion than grade 1 tumors (P=0.004) (Table 2, Figure 1b) . Deletions on 9p were also associated with larger tumors (P=0.022); 34% (18/33) of tumors 43 cm in diameter had 9p deletions compared to 16% (12/73) of tumors 43 cm (Table 2, Figure 1d ). Overall, chromosome 9 deletions were more frequent in female patients than in male patients (P=0.024); LOH were observed in 22 of 33 (67%) female patients compared to 44 of 100 (44%) male patients ( Table 2 ). The association of LOH with sex of patients was even more important in those with tumors having deletions only on 9q (P=0.01). To the opposite, no statistically signi®cant dierence was observed in 9p deletions, according to sex although all patients with 9p deletions only, were male. Patients who had a smoking history (past and current smokers) had similar frequencies of deletions as lifetime non-smokers (P=0.583). Similarly, no signi®-cant dierence was observed according to the age of patients.
Chromosome 9 deletions in relation to recurrence
The most important clinical outcome following initial TUR in this population was recurrence of super®cial tumors which occurred in 72% (96/133) of patients during follow-up (Table 1 ). The risk of recurrence during that period was higher for patients with deletions on chromosome 9: 83% of patients with bladder tumors presenting at least one LOH on chromosome 9 suered a recurrence compared to 61% of patients with tumors without chromosome 9 LOH. To determine whether speci®c regions of the chromosome were associated with a higher risk of recurrence, recurrence rate ratios associated with the deletion of each microsatellite marker were calculated using Cox proportional hazards models ( Figure 2 ). This analysis allowed us to identify ®ve markers or pairs of markers associated with a higher risk of disease recurrence (recurrence rate ratio 42), for which Kaplan-Meier recurrence-free survival curves were subsequently plotted ( Figure 3 ). LOH of markers D9S54 and/or IFNA at 9ptr-p22, D9S43 at 9p21, D9S12 and/or D9S180 at 9q22.3, D9S103 at 9q33 or ABL-1 at 9q34 were associated with a signi®cantly shorter recurrence-free survival ( Figure 3 ). The association between LOH of the dierent markers and recurrence remained signi®cant even taking into account a Bonferroni adjustment of P=0.05/5=0.01, as ®ve regions were considered (Clayton and Hills, 1993; Kleinbaum et al., 1987) . By contrast LOH of markers D9S149 and D9S66 at 9q34-qtr, both associated with a recurrence rate ratio 51, did not aect time to recurrence (Figure 3 , P=0.5). Four pathological characteristics of tumors (stage T1, grade G2-G3, tumor multifocality and a tumor diameter 43 cm) were shown to be independent predictors of tumor recurrence in multivariate analysis in the total cohort of 382 patients including the 133 studied herein (Allard et al., 1998) . However, in the present subset of 133 patients, only the number of tumors was signi®cantly associated with increased risk of recurrence in univariate analysis (RR 1.75, 95% CI, 1.137-2.687) ( Table 3) . By contrast, LOH at the ®ve sites previously described were associated with RR42 in univariate analysis. A multivariate analysis of tumor recurrence according to chromosome 9 LOH was then (Table 3 ). The association of chromosome 9 LOH with an increased risk of recurrence remained statistically signi®cant for the whole chromosome and for all the chromosome regions that showed a recurrence rate ratio 42 except for marker D9S43 at 9p21 where the association was of borderline statistical signi®cance. While tumors with LOH in the four remaining regions (9ptr-p22, 9q22.3, 9q33 or 9q34) recurred signi®cantly more often than tumors with no LOH, no dierence was observed between tumors with deletions at only one of these sites or at two or more sites simultaneously (Figure 4 ).
Chromosome 9 deletions and progression
Only four of the 133 patients included in this study progressed to muscle invasive disease. The pattern of chromosome 9 LOH for their tumor DNA is shown in Figure 5 . While these four tumors suered extensive deletions on the 9q arm, three retained all markers on the 9p arm and the fourth one retained the two most telomeric markers, which were associated with a RR42. On 9q, the markers associated with recurrence at 9q22.3, 9q33 and 9q34 have been lost in the four tumors or are non-informative. Marker D9S43 that was not signi®cantly associated with recurrence in multivariate analysis is retained in three of the tumors. Marker D9S149 which presented a RR51 is retained in one tumor.
Discussion
Several groups have reported on chromosome 9 deletions in TCC of the bladder; little attention has however been paid to the possible link between speci®c anomalies and the biological characteristics of the tumors. Most often, heterogeneous mixes of tumors have been analysed including a large proportion of higher stage and recurrent tumors. Apparent monosomy 9 was commonly observed, leaving a small sample size of tumors with partial deletions for correlative analysis. By contrast, the tumors analysed herein showed rare monosomy 9 while having subchromosomal deletions in almost half of cases, probably because they were papillary tumors obtained at ®rst diagnosis, thus likely to have suered less genetic damage. While many studies found a higher proportion of monosomy 9, at least one other study, comparing LOH analysis with in situ hybridization on 40 TCCs, concluded that complete monosomy 9 is rare in TCCs (Van Tilborg et  al., 1998) . Moreover, the tumors we analysed were collected from patients who experienced a high frequency of recurrence (72%) but rarely progressed to muscle-invasive disease (3%) during a median follow-up of 5.6 years. We had hypothesized that such a homogeneous cohort of early and highly recurrent tumors might be ideally suited to detect a possible association of chromosome 9 anomalies with tumor recurrence.
The most striking observation in the present study, was the association of chromosome 9 deletions at four loci with tumor recurrence. Few studies have looked at an association between chromosome 9 anomalies and prognosis of bladder cancer. Bartlett et al. (1998) studied monosomy 9 by Fish analysis of the pericentromeric satellite marker at 9q12 in 53 patients with pTa and pT1 tumors. They found monosomy 9 in the primary tumor of 12 out of 33 patients with subsequent tumor recurrence, by contrast to only one of 20 patients with non-recurrent tumor (P=0.0085). On the other hand, Erbersdobler et al. (1998) reported that allelic losses of microsatellite markers on 9p, 13q and 17p in 40 primary Ta and T1 bladder cancers, did not have any prognostic value regarding tumor recurrence in this group of patients. Similarly, Zhao et al. (1999) analysing chromosomal imbalances in pTa tumors by comparative genomic hybridization, found no association between 9q alterations and the risk of recurrence in 95 pTaG1/G2 tumors. In our cohort of patients, the analysis of the 28 microsatellite markers on chromosome 9 revealed four regions of deletion, which were associated with an increased risk of recurrence independent of other prognostic parameters such as stage, grade, size or number of tumors. These four regions, located at 9ptr-p22, 9q22, 9q33 and 9q34 also correspond to regions of minimal deletions suggestive of the presence of putative tumor suppressor genes that we and others have identi®ed. The INK4A gene lies close downstream to the INFA marker at 9p22, and encodes the CDKI p16, one of the sites most frequently mutated in cancer (Sharpless and Depinho, 1999) . A recent study on the same cohort of patients found a signi®cant association of INK4A homozygous deletion with a lower recurrence-free survival (P=0.040) (Orlow et al., 1999) . The 9q22 region contains the PTCH gene, located between D9S12 and D9S180, which has been suggested as a tumor suppressor gene in basal cell carcinoma (Johnson et al., 1996; Gailani et al., 1996) . The DBCCR1 gene, recently proposed as a candidate tumor suppressor gene in bladder cancer by Habuchi et al. (1998) , is located between D9S103 and GSN at 9q33. The highest RR ratio observed, except for the 9p telomeric marker, was associated with D9S103. Finally, the TSC1 gene (Hornigold et al., 1999) , also recently suggested as a bladder cancer suppressor gene lies telomeric to the ABL-1 marker at 9q34. Despite the clear association we observed between deletion in these four regions of chromosome 9 and tumor recurrence, none of these deletions could be pinpointed as the initial event in the process of carcinogenesis. Indeed, the association between deletion and tumor recurrence was independent of which one of these four regions was deleted or whether one or more was deleted. This observation suggests that tumors having deletions in any of these four regions are more likely associated with ®eld changes leading to tumor recurrence. Alternatively, it is also possible that deletion of another region on chromosome 9 overlooked in the present study could be an earlier event. Czerniak et al. (1999) , in their in-depth superimposed histologic and genetic mapping of chromosome 9 in ®ve cystectomy specimens, proposed the pericentromeric q12-13 region as the site of the critical tumor suppressor gene or genes involved in early urothelial neoplasia. This hypothesis could be consistent with our data as we analysed few microsatellite markers in the 9q12-13 region. However, their population was markedly dierent from ours and in contrast to our ®ndings, they did not identify 9q33 as a candidate region for harboring a suppressor gene. From our cohort of 133 patients, only four had tumors which progressed with recurrence to muscle invasive cancer. Of these four initial tumors, three had retained the 9p arm while the fourth had retained the two 9p telomeric markers. On the other hand, these four tumors suered extensive deletions on 9q including loss of the three loci reported herein as associated with an increased risk of recurrence. This is consistent with the data reported by Bartlett et al. (1997) who detected more frequent deletions at 9q34 in TCC from patients with recurring progressive disease.
Another unexpected observation in the present study was that deletions on the long arm of chromosome 9 were signi®cantly more frequent in female than in male patients (P=0.01), while 9p deletion were found at similar frequency. Bladder cancer is more frequent in men than in women, with a gender ratio of about 3 : 1 (Zhang and Steiner, 1997) as we observed. In another study where deletions were correlated with patient characteristics, reported a similar proportion of chromosome 9 alterations in males and females. The dierence may be due to a more heterogeneous genetic make up of their patient population than that of patients from the province of QueÂ bec, or to the limited number of their patients with super®cial tumors, providing little power to detect dierences within the subgroup of papillary low stage tumors. It is dicult to speculate about the possible signi®cance of increased frequency of 9q deletions in tumors from female patients. A few cytogenetic studies have reported that loss of sex chromosome Y, observed in approximately 50% of all bladder cancer in male patients, may be associated with a poorer clinical outcome (Sandberg and Berger, 1994; Powell et al., 1990) . It has also been suggested that survival from bladder cancer is worse in female than in male patients (Zhang and Steiner, 1997; Micheli et al., 1998) , a ®nding of interest in view of the presence of 9q deletions in all four patients with cancer progression in the present study (Micheli et al., 1998) . These sex dierences might thus re¯ect dierences in patterns of genetic alterations.
No correlation was found between anomalies of chromosome 9 and smoking status in the present cohort, an observation similar to that reported by Uchida et al. (1996) , but contrary to that of . However, a study of a subset of our patients showed a strong correlation between smoking history and presence of p53 mutations in the tumors (Larue et al., 2000) .
Correlations between chromosome 9 deletions and tumor characteristics showed signi®cantly fewer deletions in grade 1 tumors than in grades 2 ± 3 tumors. Tumors with 9p deletions were more frequently larger than 3 cm, while no such dierence was observed for 9q deletions. This observation suggests the loss of an anti-proliferative activity and is consistent with the presence on 9p of the INK4A gene encoding the p16 and p19
ARF tumor suppressor (Sharpless and Depinho, 1999) . Loss of p16 has been hypothesized to provide a selective growth advantage in many human tumors (Liggett and Sidransky, 1998) .
The correlation of chromosome 9 anomalies with clinical outcome of initial tumors provides another dimension to the analysis of their biological implications. The present study indicates that deletions at four loci are more likely associated with ®eld changes not visible at ®rst diagnosis, but leading to tumor recurrence. They also suggest that deletion of genes on the long arm of chromosome 9 may be more likely to lead to genetic instability and cancer progression.
Material and methods

Cohort of patients
Between September 1990 and April 1992, all patients consecutively admitted with newly diagnosed super®cial bladder tumors for a ®rst transurethral resection (TUR) in one of 15 participating hospitals in the province of QueÂ bec, Canada, were considered for this study. Eligible patients who met the following criteria were enrolled: (a) resected primary tumors were histologically con®rmed as stage Ta or T1 TCC; (b) written informed consent to participate in the study had been obtained (Allard et al., 1995) . At the time of diagnosis, a trained research assistant interviewed each patient and ®lled in a detailed questionnaire on smoking habits. Snap frozen samples were prepared from TUR fragments of tumoral tissue for 381 patients. Hematoxylin/eosin staining of tissue sections con®rmed that the fragments used contained more than 90% tumor cells. Blood samples were taken during follow-up visits and the questionnaire was then repeated, for validation. Pathological stage and grade for each tumor in the present study were determined by the same pathologist. For statistical analysis, grade 2 and 3 tumors were pooled, as only 9% of tumors were grade 3. Initial evaluation, treatment and follow-up schedule were standardized. Demographics, smoking history, presentation and clinicopathological data such as grade, stage, size and number of tumors were recorded. The data from each visit were entered into a database and form the basis of this study.
Microsatellite analysis
Loss of heterozygosity of 28 microsatellite markers of chromosome 9 (7 on 9p and 21 on 9q), was analysed as described (Simoneau et al., 1999) . The microsatellite markers analysed are listed in the LDB database (http://cedar. genetics.soton.ac.uk/public_html) and span the entire length of chromosome 9 at an average distance of 5 Mb, except for the 9q12-q13 region which is underrepresented. Brie¯y, blood and tumor DNA were extracted using proteinase K digestion. Prior to microsatellite analyses, a preampli®cation step was carried out as described by Zhang et al. (1992) . Microsatellite ampli®cation was subsequently carried out according to Keen and Knowles (1994) , using a g 32 P-labelled forward primers. Assessment of microsatellite patterns was made initially by visual inspection. In the 10% cases where partial deletions of one allele were observed, the autoradiograms were scanned and images analysed by NIH Image software version 1.6. LOH was de®ned as greater than 50% reduction in intensity of signal.
Statistical analyses
Duration of follow-up was calculated as the time between the date of diagnosis and the date of last contact or death. The Chi-square test was used to assess the association between chromosome 9 alterations and clinicopathological variables. Cox proportional hazards models were used to calculate recurrence rate ratio (RR) for the deletion of each microsatellite marker. These ratios were used to pinpoint regions where deletion was strongly associated with the risk of disease recurrence (RR42). Kaplan-Meier survival curves were then plotted for each region with the exposed population being subjects with a LOH at any one of the loci of the region. As a comparison, a survival curve was also plotted for a region with a RR51. Log-rank statistics were used to compare survival curves and a Bonferroni adjustment of P=0.05/5=0.01 was applied as ®ve regions were analysed (Clayton and Hills, 1993; Kleinbaum et al., 1987) . All reported P-values are two-sided. A multivariate Cox regression model was used to assess whether LOH at various loci were an independent predictor of recurrence after controlling for stage, grade, number of tumors and tumor diameter.
